The vaginal microbiota in the course of bacterial vaginosis treatment

Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):651-656. doi: 10.1007/s10096-020-04049-6. Epub 2020 Oct 7.

Abstract

Bacterial vaginosis (BV) is perceived as a condition of disrupted vaginal microbiota, but remains of unknown aetiology. In this study, vaginal microbiota composition was determined in twenty-one women with BV, before and after treatment with metronidazole or clindamycin. Microbiota composition varied greatly between women and defining a (un)healthy vaginal microbiota state remains elusive, challenging BV diagnosis and treatment. While relative abundance of Lactobacillus increased after antibiotic treatment in two-third of women, its abundance was not associated with treatment outcome. Instead, remaining complaints of abnormal vaginal discharge were more common after metronidazole treatment and associated with increased relative abundance of Ureaplasma.

Keywords: 16S rRNA gene amplicon sequencing; Antibiotics; Bacterial vaginosis; Clindamycin; Metronidazole; Microbiota.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteria / classification
  • Bacteria / drug effects
  • Bacteria / genetics
  • Bacteria / isolation & purification
  • Clindamycin / therapeutic use
  • Female
  • Host Specificity
  • Humans
  • Metronidazole / therapeutic use
  • Microbiota / drug effects*
  • RNA, Ribosomal, 16S / genetics
  • Vagina / microbiology
  • Vaginal Discharge / drug therapy
  • Vaginal Discharge / microbiology
  • Vaginosis, Bacterial / drug therapy*
  • Vaginosis, Bacterial / microbiology*

Substances

  • Anti-Bacterial Agents
  • RNA, Ribosomal, 16S
  • Metronidazole
  • Clindamycin